Prevention and treatment of the complications of diabetes mellitus

New England Journal of Medicine

Volumn 332, Issue 18, 1995, Pages 1210-1217

  Wood, Alastair J j ^a   Clark, Charles M ^a   Lee, D Anthony ^b  

^a RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALBUMIN; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; AMITRIPTYLINE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPSAICIN; CARBAMAZEPINE; CISAPRIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOMPERIDONE; EPALRESTAT; ERYTHROMYCIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METOCLOPRAMIDE; PHENYTOIN; PONALRESTAT; SORBINIL; THIAZIDE DIURETIC AGENT; TICLOPIDINE; TOLRESTAT; UNINDEXED DRUG;

ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FLUORESCENCE ANGIOGRAPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; LASER COAGULATION; MICROALBUMINURIA; MICROANGIOPATHY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN RESTRICTION; REVIEW; STOMACH PARESIS; TOPICAL DRUG ADMINISTRATION; VITRECTOMY;

DIABETES MELLITUS, INSULIN-DEPENDENT; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; HUMAN; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029069447     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199505043321807     Document Type: Review

References (93)

1. Nathan DM Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-1685
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
3. Colwell JA DCCT findings: applicability and implications for NIDDM. Diabetes Rev 1994; 2: 277-291
4. Kador PF The role of aldose reductase in the development of diabetic complications. Med Res Rev 1988; 8: 325-352
5. Raskin P, Rosenstock J Aldose reductase inhibitors and diabetic complications. Am J Med 1987; 83: 298-306
6. Brownlee M Glycation and diabetic complications. Diabetes 1994; 43: 836-841
7. Greene DA Myo-inositol: the mystery molecule of diabetic complications. Clin Diabetes 1985; 3: 80-91
8. Edelstein D, Brownlee M Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-29
9. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334
10. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci U S A 1991; 88: 6107-6111
11. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52
12. Hammes H-P, Martin S, Federlin K, Geisen K, Brownlee M Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991; 88: 11555-11558 [Erratum, Proc Natl Acad Sci U S A 1992;89:9364.]
13. Klein R, Klein BE, Moss SE Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992; 15: 1875-1891
14. Scheider A, Meyer-Schwickerath E, Nasser J, Land W, Landgraf R Diabetic retinopathy and pancreas transplantation: a 3-year follow-up. Diabetologia 1991; 34: Suppl 1: S95-S99
15. Bandello F, Vigano C, Secchi A, The influence of combined kidney-pancreas transplantation on advanced diabetic retinopathy. Transplant Proc 1992; 24: 854-854
16. Esmatjes E, Adan A, Ricart MJ, Long-term evolution of diabetic retinopathy and renal function after pancreas transplantation. Transplant Proc 1992; 24: 12-13
17. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial. N Engl J Med 1984; 311: 365-372
18. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983; 1: 200-204
19. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes V Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo Study. BMJ 1985; 290: 811-815
20. Kohner M, Caldwell G, Plehwe WE, Brown R, Rosen E Ponalrestat in early diabetic retinopathy. Diabetes 1990; 39: Suppl 1: 62A-62A abstract.
21. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990; 108: 1234-1244
22. Hotta N, Sakamoto N, Fukuda M, Epalrestat can truly prevent diabetic retinopathy in clinical double-blind study. Diabetes 1990; 39: Suppl 1: 61A-61A abstract.
23. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes 1989; 38: 491-498
24. The TIMAD Study Group. Ticlopidine treatment reduces the progression of non-proliferative diabetic retinopathy. Arch Ophthalmol 1990; 108: 1577-1583
25. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Ophthalmology 1991; 98: Suppl: 757-765
26. American Diabetes Association. Screening for diabetic retinopathy. Diabetes Care 1993; 16: 16-18
27. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology 1981; 88: 583-600
28. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796-1806
29. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. DRVS report number 2. Arch Ophthalmol 1985; 103: 1644-1652
30. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978; 85: 82-106
31. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991; 98: Suppl: 766-785
32. Blackenship GW, Machemer R Long-term diabetic vitrectomy results: report of 10 year follow-up. Ophthalmology 1985; 92: 503-506
33. United States renal data system 1991 annual data report. Am J Kidney Dis 1991; 18: Suppl 2-Suppl 2
34. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994; 330: 15-18
35. Christiansen JS, Gammelgaard J, Frandsen M, Parving HH Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics. Diabetologia 1981; 20: 451-456
36. Hostetter TH, Rennke HG, Brenner BM The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380
37. Vannini P, Ciavarella A, Flammini M, Lipid abnormalities in insulin-dependent diabetic patients with albuminuria. Diabetes Care 1984; 7: 151-154
38. Raskin P, Pietri AO, Unger R, Shannon WA The effect of diabetic control on the width of skeletal-muscle capillary basement membrane in patients with Type I diabetes mellitus. N Engl J Med 1983; 309: 1546-1550
39. Christensen CK, Christiansen JS, Schmitz A, Christensen T, Hermansen K, Mogensen CE Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. J Diabetes Complications 1987; 1: 91-95
40. Beck-Nielsen H, Richelsen B, Mogensen CE, Effect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care 1985; 8: 585-589
41. Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. Acta Endocrinol Suppl (Copenh) 1988; 117: 19-25
42. Feldt-Rasmussen B, Mathiesen ER, Deckert T Effect of two years strict metabolic control on the progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; 2: 1300-1304
43. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
44. Melchior WR, Bindlish V, Jaber LA Angiotensin-converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother 1993; 27: 344-350
45. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581
46. American Diabetes Association, National Kidney Foundation. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994; 17: 1357-1361
47. Mogensen CE Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383-388
48. Mogensen CE Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685-688
49. Parving HH, Andersen AR, Smidt UM, Svendsen PA Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-1179
50. Aubia J, Hojman L, Chine M, Hypertension and nephrotoxicity in the rate of decline in kidney function in diabetic nephropathy. Clin Nephrol 1987; 27: 15-20
51. Berglund J, Lins LE, Lins PE Metabolic and blood pressure monitoring in diabetic renal failure. Acta Med Scand 1985; 218: 401-408
52. Viberti GC, Wiseman M, Mackintosh D, Janett RJ, Keen H Microalbuminuria and marginal blood pressure changes in insulin-dependent diabetes. Diabet Nephrop 1985; 4: 32-33
53. Walker WG, Hermann J, Murphy R, Patz A Elevated blood pressure and angiotensin II are associated with accelerated loss of renal function in diabetic nephropathy. Trans Am Clin Climatol Assoc 1985; 97: 94-104
54. Stein PP, Black HR Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991; 14: 425-448
55. Parving H-H, Kastrup J, Smidt UM Reduced transcapillary escape of albumin during acute blood pressure-lowering in type I (insulin-dependent) diabetic patients with nephropathy. Diabetologia 1985; 28: 797-801
56. Evanoff GV, Thompson CS, Brown J, Weinman EJ The effect of dietary protein restriction on the progression of diabetic nephropathy: a 12-month follow-up. Arch Intern Med 1987; 147: 492-495
57. Kuysen GA, Gambertoglio J, Jimenez I, Jones H, Hutchison FN Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int 1986; 29: 572-577
58. Walker JD, Bending JJ, Dodds RA Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989; 2: 1411-1415 [Erratum, Lancet 1989;2:1540.]
59. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 78-84
60. Mogensen CE, Christensen CK Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311: 89-93
61. Fagius J, Brattberg A, Jameson S, Berne C Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 1985; 28: 323-329
62. Yagihashi S, Kamijo M, Ido Y, Mirrlees DJ Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy: ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes 1990; 39: 690-696
63. Judzewitsch RG, Jaspan JB, Polonsky KS, Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983; 308: 119-125
64. Christensen JEJ, Varnek L, Gregersen G The effect of an aldose reductase inhibitor (sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study. Acta Neurol Scand 1985; 71: 164-167
65. O'Hare JP, Morgan MH, Alden P, Chissel S, O'Brien IAD, Corrall RJM Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. Diabet Med 1988; 5: 537-542
66. Sima AAF, Bril V, Nathaniel V, Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988; 319: 548-555
67. Greene DA, Bochenek W, Harati Y, Biochemical and morphometric response to tolrestat in human diabetic nerve. Diabetologia 1990; 33: Suppl: A92-A92 abstract.
68. Gonen B, Bochenek W, Beg M, Graepel J The effect of withdrawal of tolrestat, aldose reductase inhibitor, on signs, symptoms and nerve function in diabetic neuropathy. Diabetologia 1991; 34: Suppl: A153-A153 abstract.
69. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-1256
70. Fitzgerald M Capsaicin and sensory neurons -- a review. Pain 1983; 15: 109-130
71. Ward JD Diabetic neuropathies: current concepts in prevention and treatment. Drugs 1986; 32: 279-289
72. Apfel SC, Kessler JA Diabetic neuropathy: current management and future treatments. Drug Ther 1993; 5: 17-29
73. Janssens J, Peeters TL, Vantrappen G, Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. N Engl J Med 1990; 322: 1028-1031
74. Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med 1982; 96: 444-446
75. Feldman M, Smith HJ Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum: a comparison with metoclopramide and placebo. Gastroenterology 1987; 92: 171-174
76. Horowitz M, Maddox A, Harding PE, Effect of cisapride on gastric esophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987; 92: 1899-1907
77. Johnson AG The effects of cisapride on antroduodenal co-ordination and gastric emptying. Scand J Gastroenterol Suppl 1989; 165: 36-43
78. Horowitz M, Roberts AP Long-term efficacy of cisapride in diabetic gastroparesis. Am J Med 1990; 88: 195-196
79. Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJC Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985; 30: 1-9
80. Sutherland DER, Gores PF, Farney AC, Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. Am J Surg 1993; 166: 456-491
81. Pedersen MM, Christiansen JS, Mogensen CE Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition. Diabetes 1991; 40: 527-531
82. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430-1432
83. Mogensen CE, Damsgaard EM, Froland A, Nielsen S, de Fine Olivarius N, Schmitz A Microalbuminuria in non-insulin-dependent diabetes. Clin Nephrol 1992; 38: Suppl 1: S28-S39
84. Department of Health and Human Services. The prevention and treatment of the complications of diabetes mellitus: a guide for primary care practitioners. Washington, D.C.: Government Printing Office, 1991.
85. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16: 996-1003
86. Mattock MB, Morrish NJ, Viberti V, Keen H, Fitzgerald AP, Jackson G Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992; 41: 736-741
87. Rowe DJF, Dawnay A, Watts GF Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 1990; 27: 297-312
88. Tiu SC, Lee SS, Cheng MW Comparison of six commercial techniques in the measurement of microalbuminuria in diabetic patients. Diabetes Care 1993; 16: 616-620
89. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300: 975-978
90. Warram JH, Laffel LMB, Valsania P, Christlieb AR, Krolewski AS Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991; 151: 1350-1356
91. Bakris GL, Barnhill BW, Sadler R Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41: 912-919
92. Murray KM Calcium-channel blockers for treatment of diabetic nephropathy. Clin Pharm 1991; 10: 862-865
93. Abraira C, Emanuele N, Colwell J, Glycemic control and complications in type II diabetes: design of a feasibility trial. Diabetes Care 1992; 15: 1560-1571